Ablynx appoints new commercial head
This article was originally published in Scrip
Executive Summary
Ghent, Belgium-based Ablynx, a biopharmaceutical company developing nanobodies, has named Johan Heylen chief commercial officer. He will assume responsibility for all Ablynx's commercial activities and has more than 20 years of experience in global biopharmaceutical sales, marketing and business development at GlaxoSmithKline, Servier and Wyeth. Most recently, Mr Heylen was executive director, global commercial lead of cancer immunotherapeutics at GSK.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.